Delandistrogene moxeparvovec

PreclinicalGene therapy

Delandistrogene moxeparvovec is a gene therapy that works as a Micro-Dystrophin Gene Therapy.[1] It is being investigated across 1 indication, with its most advanced program in Preclinical.

Delandistrogene moxeparvovec is one of 25 gene therapy programs targeting Duchenne Muscular Dystrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2]

Indication

Duchenne Muscular DystrophyUnknown

Duchenne Muscular DystrophyPreclinical

Unknown

Competition

Competitive Landscape

40 competitors in Duchenne Muscular Dystrophy

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Approved

—2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Coreg

Akero Therapeutics

Approved

1 4

Rapamune

PPrism Pharmaceuticals

Approved

1 5

Garamycin

Advil

Rifadin

1 8

Duvyzat

Italfarmaco

Phase 3

2 9

Vyondys 53

Sarepta Therapeutics

Approved

2 10

Agamree

CCatalyst Pharmaceuticals, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Sources

References

[1]
ChEMBL — Delandistrogene moxeparvovec compound record. European Bioinformatics Institute (EMBL-EBI).
[2]
Open Targets Platform — Drug–disease associations for Delandistrogene moxeparvovec. EMBL-EBI & Wellcome Sanger Institute.
[3]
PubMed — 10 publications indexed for Delandistrogene moxeparvovec. U.S. National Library of Medicine.
[4]
SEC EDGAR — Sarepta Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Micro-Dystrophin Gene Therapy[1]
Modality: Gene therapy[1]
Highest Phase: Preclinical
Company: Sarepta Therapeutics

Key Publications[3]

The Role of the Antidepressants in Managing Chemotherapy-Induced Neuropathic Pain: A Systematic Review.

Pharmacol Res PerspectOct 1, 2026DOI: 10.1002/prp2.70327

Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.

CancerOct 1, 2026DOI: 10.1002/cncr.70613

Metformin Attenuates Behavioral Deficits and Oxidative Stress in a Preclinical Model of Autism.

Dev NeurobiolOct 1, 2026DOI: 10.1002/dneu.70061

Impacts of a Statewide Prescription Drug Monitoring Program-Healthcare Practitioner Perspectives.

Pharmacol Res PerspectOct 1, 2026DOI: 10.1002/prp2.70326

Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome.

J Comp Eff ResSep 18, 2026DOI: 10.57264/cer-2026-0138

Suboptimal management of Staphylococcus aureus bacteremia: a retrospective case series from a Nigerian tertiary hospital.

Trans R Soc Trop Med HygSep 18, 2026DOI: 10.1093/trstmh/trag111

Early diagnosis of axial spondyloarthritis is associated with less long-term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management in rheumatic diseases registry.

Arthritis RheumatolSep 18, 2026DOI: 10.1002/art.70346

Two-Year Outcome of Partial Pulpotomy Using Mineral Trioxide Aggregate or a Premixed Calcium Silicate Cement: A Randomized Clinical Trial.

Int Endod JSep 18, 2026DOI: 10.1111/iej.70274

Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study).

Br J Clin PharmacolSep 18, 2026DOI: 10.1002/bcp.70832

Patient Safety Gaps in Rheumatology: A Mixed-Methods Study.

J Patient SafSep 18, 2026DOI: 10.1097/PTS.0000000000001586

Delandistrogene moxeparvovec

Status by Indication[2]

Competitive Landscape

References

Drug Info

Quick Facts

Key Publications[3]

Related News